Intrinsic Value of S&P & Nasdaq Contact Us

Akili, Inc. AKLI NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Healthcare Information Services • US • USD

SharesGrow Score
48/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$3.25
+650.4%

Akili, Inc. (AKLI) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 2 recommend buying, 2 recommend holding, and 0 recommend selling.

The analyst consensus price target for AKLI is $3.25, representing a +650.4% upside from the current price of $0.4331. Price targets range from a low of $2.00 to a high of $4.50.

Analyst Consensus — AKLI

Buy
Strong Buy
0
Buy
2
Hold
2
Sell
0
Strong Sell
0
4 analysts
Price Targets
Consensus$3.25
High$4.50
Low$2.00
Median$3.25
Last Month Avg-
Last Quarter Avg-
Last Year Avg-
All-Time Count2
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message